Cat. No. Name Size Price Add Cart
KI0408MK-2206 2HCl5 mg$176
MK-2206 2HCl10 mg$270
MK-2206 2HCl25 mg$440
MK-2206 2HCl50 mg$736

Chemical Characteristic

Product NameMK-2206 2HCl
CAS No.1032350-13-2
Molecular Weight 480.39
FormulaC25H21N5O.2HCl
Chemical Name8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride
Smilesn1c(c(cc2c3n(ccc12)c(=O)[nH]n3)c1ccccc1)c1ccc(cc1)C1(CCC1)N Cl Cl
Chemical Structure

Biological activities

MK-2206 is a highly selective non-ATP competitive allosteric Akt inhibitor that is equally potent towards purified recombinant human Akt1 and Akt2 and approximately five fold less potent against human Akt3 (IC50= 8, 12, and 65 nM, respectively) in enzyme assays. MK-2206 (0-10 μM) decreases both Thr 308 and Ser 473 p-Akt levels in T-cell acute lymphoblastic leukemia (T-ALL) cell lines, MOLT-4, CEM-R and CEM-S , in a concentration-dependent manner, resulting in dephosphorylation of GSK3-α/β (Ser 21/9 ) and FoxO3A (Thr-32). MK-2206 also decreases the levels of Ser 2481 p-mTOR. The IC50 values of MK-2206 are 1.7, 3.3 and 5.1 μM for T-ALL cell lines, MOLT-4, CEM-R and CEM-S, respectively. MK-2206 treatment (1-3 μM) results in an increase in MOLT-4 cells in the G0/G1 phase and in a decrease in cells in S phase in a concentration-dependent manner. The levels of colony-forming unit (CFU)-leukemia formation from three different T-ALL samples are markedly reduced with a mean decrease from 63 to 21%, after treatment with 0.5??.0 μM MK-2206.[1] The median relative IC50 value of MK-2206 for the Pediatric Preclinical Testing Program (PPTP) cell lines is 2.2 μM, with a range from 0.05 μM for the T-cell ALL line COG-LL-317 to greater than 10 μM for the glioblastoma cell line SJ-GBM2. There are four cell lines with IC50 values of MK-2206 < 200 nM: two acute lymphoblastic leukemia (ALL) cell lines (COG-LL-317 and RS4;11), an acute myelocytic leukemia (AML) cell line with an activating KIT mutation (Kasumi-1), and a Ewing sarcoma cell line (CHLA-10).[2] In human glioma LN229 and T98G cells, Akt inhibition by MK-2206 (2.5, 5 or 10 μM) or siRNA-mediated attenuation strongly activates autophagy, whereas silencing of eukaryotic elongation factor-2 (eEF-2) kinase, a protein synthesis regulator, blunts this autophagic response.[3] In HCC70 human breast carcinoma xenograft model, MK-2206 (120 mg/kg) alone shows moderate tumor growth inhibition and the combination of lapatinib (100 mg/kg) and MK-2206 (120 mg/kg) has a significantly greater inhibition of HCC70 tumor growth than either agent alone. Besides, in SK-OV-3 human ovarian cancer xenograft model, lapatinib (100 mg/kg) or MK-2206 (120 mg/kg) alone moderately inhibits SK-OV-3 tumor growth, the combination of lapatinib (100 mg/kg) and MK-2206 (120 mg/kg) yields a significantly greater antitumor effect than either agent alone, and in a dose-dependent manner. In a PC-3 xenograft model (human prostate cancer cell line), docetaxel (5 mg/kg) or MK-2206 (120 mg/kg) alone shows moderate antitumor efficacy and cotreatment with docetaxel followed by MK-2206 exhibits greater tumor growth inhibition than each agent alone. Mice who received docetaxel alone, MK-2206 alone, or both agents lose body weight (4%, 8%, and 9%, respectively) during the treatment period. However, their weight returns to the pretreatment level after the end of treatments.[4]

References

[1] Simioni C et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia. 2012.
[2] Gorlick R, et al. Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012, 59(3): 518-524.
[3] Cheng Y, et al. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Res. 2011, 71(7): 2654-2663.
[4] Hirai H, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010, 9(7): 1956-1967.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.
KareBayTM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.